Novi vs SkinnyRx: Cheapest GLP-1 Access, Support, and Medication Options in 2026

The short answer

Choose Novi if you want the cleaner all-in package. Novi lists compounded semaglutide from $174 per month and compounded tirzepatide from $283 per month. The price includes the clinician review, medication if prescribed, supplies, free 2-day shipping, clinician support, and coaching.

Choose SkinnyRx if you want to pick semaglutide or tirzepatide directly and you do not need much coaching. PeptidePub tracks SkinnyRx injectable semaglutide from $149.25 per month and tirzepatide around $299 per month, with free shipping and no separate membership fee.

Neither provider is the same as getting brand-name Wegovy or Zepbound through insurance. This is mainly a comparison of compounded GLP-1 telehealth access, so pharmacy quality, prescribing oversight, and cancellation terms matter as much as headline price.

Pricing side by side

The pricing verdict is close. SkinnyRx can win on the lowest semaglutide number. Novi wins if you value a bundled program where coaching and clinician support are explicitly included. On tirzepatide, the difference is small enough that support model and terms may matter more than the headline price.

Support and coaching are the biggest difference

Novi is built more like a bundled GLP-1 program. The company says the monthly price includes a 4-week supply if prescribed, supplies, unlimited clinician support for check-ins, dose adjustments, and questions, plus coaching at no additional cost.

SkinnyRx is more direct. It gives buyers separate semaglutide and tirzepatide paths, provider review, medication fulfillment, and support for refills or dose changes. That can be enough if you are already comfortable managing food, protein, side effects, and follow-up questions.

The practical question is whether you want medication access or a fuller program. If you want someone checking in on habits and tolerability, Novi has the stronger pitch. If you want fewer extras and a faster purchase path, SkinnyRx may feel simpler.

Medication options and expected results

Both providers focus on GLP-1 medications used for weight loss, especially compounded semaglutide and tirzepatide. The strongest weight-loss evidence comes from the FDA-approved injectable products, not from every compounded format sold online.

In STEP 1, Wilding and colleagues reported in the New England Journal of Medicine in 2021 that once-weekly semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo. In SURMOUNT-1, Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that tirzepatide produced 16.0%, 21.4%, and 22.5% mean weight loss at 72 weeks across the 5 mg, 10 mg, and 15 mg groups, versus 2.4% with placebo.

Those numbers explain why buyers look for lower-cost GLP-1 access. They do not prove that every compounded product, formulation, dose schedule, or telehealth pathway performs the same way. Use trial data as a benchmark, not a guarantee.

Safety and regulatory caveats

Compounded GLP-1 drugs are not FDA-approved products. FDA has warned about dosing errors with compounded semaglutide, including adverse events that required hospitalization, often tied to patients measuring the wrong dose or providers calculating doses incorrectly.

FDA also clarified in April 2026 that compounders must still meet the conditions under sections 503A and 503B of the FD&C Act. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound those drugs from bulk substances.

Buyer checklist: verify the prescriber is licensed, ask which pharmacy fills the medication, confirm whether the product is injectable or oral, get clear dosing instructions in units and milligrams, and understand what happens if you cancel after a prescription has already shipped.

Reviews, cancellation, and friction points

Novi states its program is month to month with no minimum commitment or long-term contract. It also says shipped or dispensed prescriptions cannot be returned or refunded, and cancellation stops future renewals. That is typical for prescription medication, but it matters if you are comparing refund risk.

SkinnyRx also describes cancellation for future ongoing subscription months. The most common buyer confusion across GLP-1 subscriptions is the difference between canceling future renewals and trying to refund medication that has already been prescribed, filled, or shipped.

Read reviews for patterns, not isolated complaints. Delivery timing, support response, pharmacy transparency, and billing clarity are more useful signals than generic claims that a provider is either perfect or a scam.

Decision framework

FAQ

Bottom line

Novi is the better first check for buyers who want low all-in pricing plus coaching. SkinnyRx is the better first check for buyers who want a simple, self-directed GLP-1 order flow and clear semaglutide or tirzepatide paths.

If price is close, choose based on support depth, dose clarity, pharmacy transparency, and cancellation terms. The cheapest GLP-1 program is not a bargain if the prescribing workflow or dosing instructions leave you guessing.

Sources

1. JoinNovi.com. Novi GLP-1 program pricing, included services, shipping, and cancellation terms. Accessed June 12, 2026.
2. SkinnyRx.com. GLP-1 weight loss telemedicine pages and FAQ. Accessed June 12, 2026.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.
6. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026.
7. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. April 30, 2026.